Apitope Raises Series A

Apitope International, a UK-based developer of vaccines and diagnostics for autoimmune and allergic diseases, has raised 10 million in Series A funding. LRM and Vesalius Biocapital co-led the round, and were joined by VINNOF and the University of Hasslet. Innovator Capital served as placement agent. www.apitope.com